Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1

Interventions

Rituximab 205Cyclophosphamide 178Peripheral Blood Stem Cell Transplantation 93Etoposide 91fludarabine phosphate 86Filgrastim 81Melphalan 62Vincristine 60Mycophenolic Acid 58Busulfan 58Whole-Body Irradiation 57Cytarabine 51Radiotherapy 49Doxorubicin 49Cyclosporine 49Tacrolimus 48Granulocyte Colony-Stimulating Factor 48Prednisone 46fludarabine 45Bendamustine Hydrochloride 45Methotrexate 44Carmustine 36Antilymphocyte Serum 34Dexamethasone 32Bortezomib 29Gemcitabine 27ibritumomab tiuxetan 25Methylprednisolone 23sargramostim 22Stem Cell Transplantation 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Non-Hodgkin × Pentetic Acid × Clear all
NCT00001575 2015-12-07

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
87 enrolled 11 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡